EverSource Wealth Advisors’s NovoCure NVCR Stock Holding History

EverSource Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.2K	Buy	1,138 +556	+96%	+$8.41K	﹤0.01%	2551
2026 Q1	$6.34K	Buy	582 +323	+125%	+$4.03K	﹤0.01%	3154
2025 Q4	$3.35K	Buy	259 +172	+198%	+$2.21K	﹤0.01%	3292
2025 Q3	$1.12K	Buy	87 +13	+18%	+$174	﹤0.01%	3732
2025 Q2	$1.32K	Buy	74 +12	+19%	+$209	﹤0.01%	3657
2025 Q1	$1.1K	Sell	62 -2	-3%	-$45	﹤0.01%	3194
2024 Q4	$1.91K	Buy	64 +26	+68%	+$550	﹤0.01%	2727
2024 Q3	$594	Hold	38	–	–	﹤0.01%	2834
2024 Q2	$865	Hold	38	–	–	﹤0.01%	2766
2024 Q1	$465	Buy	+38	New	+$559	﹤0.01%	2742
2023 Q4	–	Sell	-23	Closed	-$372	–	2712
2023 Q3	$372	Buy	23 +17	+283%	+$490	﹤0.01%	2425
2023 Q2	$249	Hold	6	–	–	﹤0.01%	2410
2023 Q1	$361	Hold	6	–	–	﹤0.01%	2281
2022 Q4	$440	Sell	6 -6	-50%	-$451	﹤0.01%	2226
2022 Q3	$0	Hold	12	–	–	﹤0.01%	2078
2022 Q2	$0	Hold	12	–	–	﹤0.01%	1837
2022 Q1	$0	Buy	+12	New	+$884	﹤0.01%	1802

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

EverSource Wealth Advisors's NVCR Position: Q2 2026 in Review

EverSource Wealth Advisors increased its NovoCure (NVCR) stake by 96% in Q2 2026, buying an estimated $8.41K and bringing the position to 1,138 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2551.

EverSource Wealth Advisors first reported a position in NVCR in Q1 2022 and has held it in 17 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

EverSource Wealth Advisors held 1,138 shares of NovoCure worth $17.2K as of Q2 2026.
EverSource Wealth Advisors bought 556 NovoCure shares in Q2 2026, an estimated $8.41K.
NovoCure made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2551 holding.
EverSource Wealth Advisors first reported a position in NovoCure in Q1 2022 and has held it in 17 quarters since.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.